Ftse Mib
38.379,64
1,06%
DAX
22.795,35
1,39%
S&P 500
6.114,63
-0,01%
NASDAQ
20.026,77
0,41%
Bitcoin
95.627,74
-0,52%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neumora Therapeutics Inc (NMRA) Neumora Therapeutics Inc (NMRA) Notizie

Neumora Therapeutics Inc

NMRA
1,73
0,04 (2,37%)
15 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/2/202522:51EDGAR2Form 8-K - Current report
13/2/202513:00GLOBENeumora Therapeutics Announces Leadership Transition
13/2/202511:45PRNUSClass Action Filed Against Neumora Therapeutics, Inc. (NMRA)..
13/1/202514:00EDGAR2Form 8-K - Current report
03/1/202500:40BWNeumora Therapeutics, Inc. Investigated for Securities Fraud..
02/1/202513:10EDGAR2Form 8-K - Current report
02/1/202513:00GLOBENeumora Therapeutics Reports Data from KOASTAL-1 Study of..
22/11/202423:33EDGAR2Form SC 13D/A - General Statement of Acquisition of..
12/11/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202413:17EDGAR2Form 8-K - Current report
12/11/202413:00GLOBENeumora Therapeutics Reports Third Quarter 2024 Financial..
06/11/202413:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
29/10/202412:00GLOBENeumora Therapeutics to Report Third Quarter 2024 Financial..
11/10/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202422:30EDGAR2Form 144 - Report of proposed sale of securities
09/10/202422:10EDGAR2Form 144 - Report of proposed sale of securities
01/10/202423:22EDGAR2Form S-3ASR - Automatic shelf registration statement of..
19/9/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202422:27EDGAR2Form 144 - Report of proposed sale of securities
17/9/202422:37EDGAR2Form 144 - Report of proposed sale of securities
16/9/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202423:18EDGAR2Form 144 - Report of proposed sale of securities
27/8/202423:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/8/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202415:48EDGAR2Form 144 - Report of proposed sale of securities
14/8/202413:00GLOBENeumora Therapeutics to Host Key Opinion Leader Roundtable..
06/8/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/8/202413:15EDGAR2Form 8-K - Current report
06/8/202413:00GLOBENeumora Therapeutics Reports Second Quarter 2024 Financial..
20/6/202413:00GLOBENeumora Therapeutics Announces Initiation of Phase 1b Study..
14/6/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:01EDGAR2Form 8-K - Current report
14/5/202413:00GLOBENeumora Therapeutics Announces Initiation of Phase 2 Study..
07/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:15EDGAR2Form 8-K - Current report
07/5/202413:00GLOBENeumora Therapeutics Reports First Quarter 2024 Financial..
06/5/202413:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
15/4/202412:30GLOBENeumora Therapeutics Announces Clinical Hold of Phase 1..
13/3/202412:00GLOBENeumora Therapeutics to Participate at Stifel 2024 Virtual..
07/3/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202413:08EDGAR2Form 8-K - Current report
07/3/202413:00GLOBENeumora Therapeutics Reports Fourth Quarter and Full Year..
Apertura: 1,72 Min: 1,70 Max: 1,795
Chiusura: 1,69

La tua Cronologia

NASDAQ
NMRA
Neumora Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci